ATLANTA, Aug. 2, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., a biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today the appointment of Nathan Andrew Shapira, M.D., Ph.D. as Executive Director of Clinical Research and Development and Deputy Chief Medical Officer. Dr. Shapira will help to lead teams of researchers in the design, development, and execution of clinical development programs for Tikvah Therapeutics' neurological and psychiatric pharmaceutical products.
Dr. Shapira joins Tikvah Therapeutics with extensive global pharmaceutical industry and academic experience in the design, development, and reporting of clinical trials in various therapeutic areas. He was most recently director and member of the leadership team of the Neuroscience Department, Clinical Development and Medical Affairs at Solvay Pharmaceuticals where he helped to direct its Schizophrenia and Parkinson's Disease clinical development programs.
Prior to his role with Solvay Pharmaceuticals, Dr. Shapira was an Assistant Professor of Psychiatry in the Department of Psychiatry of the College of Medicine at the University of Florida. During his academic career, Dr. Shapira specialized in the research of the psychopharmacologic treatment of anxiety, mood and impulse control disorders, and in particular, the understanding of the pathophysiology and neurocircuitry of obsessive-compulsive and eating disorders. He has been an investigator on numerous industry and government sponsored clinical trials and is widely published, having authored more than 100 articles and book chapters. He also is an inventor on seven patent/patent applications related to the treatment of a broad range of neuropsychiatric and other medical disorders.
Dr. Shapira serves as a Clinical Assistant Professor of Psychiatry and Behavioral Sciences at the Emory University School of Medicine. He also serves as an Adjunct Assistant Professor of Psychiatry at the University of Florida College of Medicine.
Dr. Shapira is a member of the American Medical Association, American Psychiatric Association, Society of Biological Psychiatry, and the International Society of CNS Clinical Trials and Methodology, amongst others. He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Shapira earned his BS degree in Chemistry and Biology at Emory University, his MD and PhD degrees at Vanderbilt University School of Medicine, and completed his psychiatric residency at the University of Cincinnati Medical Center.
Bringing Hope to Life....(sm)
About Tikvah Therapeutics, Inc.
Atlanta-based Tikvah Therapeutics, Inc. focuses on exploring new uses for late-stage pharmaceutical compounds in selected therapeutic indications of central nervous system diseases, including neurology and psychiatry disorders. Its focus is on new therapeutic uses that have been confirmed in multiple, clinical proof-of-concept studies. This strategy shortens product development timelines and substantially decreases the risk associated with the research and development efforts. A second prong of its strategy is to focus on specialized products with multiple stepping-stone indications and strong patent protections, thus helping to ensure long product life cycles and manageable commercial risk. Tikvah Therapeutics was founded by Paramount BioSciences, LLC. For additional information about Tikvah Therapeutics, please visit www.tikvahtherapeutics.com.
The Tikvah Therapeutics, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3966
Note to Editor: A photo of Dr. Shapira is available upon request.
"TIKVAH THERAPEUTICS, INC.," "Bringing Hope to Life," and the above logo design are trademarks of Tikvah Therapeutics, Inc., Atlanta, Georgia USA